Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Cogent Biosciences, Inc. (COGT)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
14.13+0.68 (+5.06%)
At close: 04:00PM EDT
14.53 +0.40 (+2.83%)
After hours: 07:54PM EDT
Advertisement

Cogent Biosciences, Inc.

200 Cambridge Park Drive
Suite 2500
Cambridge, MA 02140
United States
617 945 5576
https://www.cogentbio.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees77

Key Executives

NameTitlePayExercisedYear Born
Mr. Andrew R. Robbins M.B.A.Pres, CEO & Director961.32kN/A1976
Dr. John Edward Robinson Ph.D.Chief Scientific Officer560.22kN/AN/A
Dr. Jessica Sachs M.D.Chief Medical Officer595.24kN/A1975
Mr. John L. Green C.A., CPACFO & Principal Accounting OfficerN/AN/A1980
Mr. Brad BarnettChief Technology OfficerN/AN/AN/A
Mr. Evan D. Kearns J.D.Chief Legal Officer & Corp. Sec.N/AN/A1980
Ms. Erin SchellhammerChief People OfficerN/AN/AN/A
Ms. Sara SaltzmanSr. VP of Regulatory AffairsN/AN/AN/A
Mr. Dana R. Martin Pharm.D.Sr. VP of Medical Affairs & Chief Patient OfficerN/AN/AN/A
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. It has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Corporate Governance

Cogent Biosciences, Inc.’s ISS Governance QualityScore as of July 31, 2022 is 8. The pillar scores are Audit: 9; Board: 6; Shareholder Rights: 8; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Advertisement
Advertisement